<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Genom Data</journal-id><journal-id journal-id-type="iso-abbrev">Genom Data</journal-id><journal-title-group><journal-title>Genomics Data</journal-title></journal-title-group><issn pub-type="epub">2213-5960</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26484264</article-id><article-id pub-id-type="pmc">4584013</article-id><article-id pub-id-type="publisher-id">S2213-5960(15)00091-4</article-id><article-id pub-id-type="doi">10.1016/j.gdata.2015.05.028</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data in Brief</subject></subj-group></article-categories><title-group><article-title>Aristolochic acids &#x02014; Induced transcriptomic responses in rat renal proximal tubule cells <italic>in vitro</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bloch</surname><given-names>Katarzyna M.</given-names></name><email>K.Bloch@liv.ac.uk</email><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Evans</surname><given-names>Andrew</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lock</surname><given-names>Edward A.</given-names></name></contrib></contrib-group><aff id="af0005">Liverpool John Moores University, Liverpool, UK</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author. <email>K.Bloch@liv.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>01</day><month>6</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>01</day><month>6</month><year>2015</year></pub-date><volume>5</volume><fpage>254</fpage><lpage>256</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 The Authors</copyright-statement><copyright-year>2015</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract><p>Aristolochic acids (AAs) are the active components of herbal drugs derived from <italic>Aristolochia</italic> species that have been used for medicinal purposes since antiquity. However, AAs have recently been discovered to be highly nephrotoxic and induced urothelial cancer in humans and malignant tumors in the kidney and urinary tract of rodents. In this study, we exposed rat renal proximal tubule cells <italic>in vitro</italic> to a sub-cytotoxic level of AAs at three different time points (6&#x000a0;h, 24&#x000a0;h and 72&#x000a0;h). We then analyzed the gene expression profile after the compound exposure. Functional analysis with Ingenuity Pathways Analysis and DAVID tools revealed that at the late time point (72&#x000a0;h) there are many significantly altered genes involved in cancer-related pathways such as p53 signaling.</p><p>MIAMI-compliant microarray data are deposited in the NCBI GEO database under accession number <ext-link ext-link-type="uri" xlink:href="ncbi-geo:GSE68687" id="ir0005">GSE68687</ext-link> and can be found at: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687" id="ir0010">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687</ext-link>.</p></abstract><kwd-group><title>Keywords</title><kwd>Aristolochic acid</kwd><kwd>Genotoxic</kwd><kwd>Carcinogen</kwd><kwd>Rat renal proximal tubule cells</kwd><kwd>Microarray</kwd></kwd-group></article-meta></front><body><p><table-wrap id="t0020" position="float"><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left">Specifications</th></tr></thead><tbody><tr><td align="left">Organism/cell line/tissue</td><td align="left">Rat/NRK-52E cells (ATCC, CRL-1571)</td></tr><tr><td align="left">Sex</td><td align="left">Male</td></tr><tr><td align="left">Sequencer or array type</td><td align="left">Affymetrix Rat Genome 230 2.0 Array</td></tr><tr><td align="left">Data format</td><td align="left">Raw and analyzed</td></tr><tr><td align="left">Experimental factors</td><td align="left">Normal rat renal proximal tubule cells exposed to 1.65&#x000a0;&#x003bc;M aristolochic acids for 6&#x000a0;h, 24&#x000a0;h and 72&#x000a0;h as well as time-matched controls exposed to DMSO alone</td></tr><tr><td align="left">Experimental features</td><td align="left">NRK-52E cells were exposed to aristolochic acids dissolved in DMSO (0.1%) at the IC<sub>10</sub> concentration at 72&#x000a0;h (1.65&#x000a0;&#x003bc;M) or DMSO only as control. After 6&#x000a0;h, 24&#x000a0;h and 72&#x000a0;h RNA was extracted from the cells. Three studies were conducted at each time point.</td></tr><tr><td align="left">Consent</td><td align="left">NA</td></tr><tr><td align="left">Sample source location</td><td align="left">NRK-52E cells (ATCC, CRL-1571), Liverpool, UK</td></tr></tbody></table></table-wrap></p><sec id="s0005"><label>1</label><title>Direct link to deposited data</title><p><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687" id="ir0015">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687</ext-link>.</p></sec><sec id="s0010"><label>2</label><title>Introduction</title><p>Aristolochic acids (AAs) are a mixture of structurally related nitrophenanthrene carboxylic acids, mainly 8-methoxy-6-nitrophenanthro [3,4-<italic>d</italic>] 1,3-dioxolo-5-carboxylic acid (aristolochic acid I) and its 8-demethoxylated form (aristolochic acid II) (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) that are secondary metabolites of <italic>Aristolochia</italic> and <italic>Asarum</italic> plant species.</p><p>Herbal drugs containing aristolochic acids have been used since antiquity, however in 1982, AAs were reported to be highly carcinogenic in rats causing renal and forestomach cancers <xref rid="bb0005" ref-type="bibr">[1]</xref>, <xref rid="bb0010" ref-type="bibr">[2]</xref>. Later similar findings were reported in mice <xref rid="bb0015" ref-type="bibr">[3]</xref>. In 1991, a unique and rapidly progressive renal fibrosis referred as Aristolochic Acid Nephropathy (AAN), was observed in around 5% of patients that took weight-reducing pills containing AAs <xref rid="bb0020" ref-type="bibr">[4]</xref>. Over 100 cases of AAN have been identified with around half needing renal transplantation <xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>. AA consumption (as harvest contamination) is also hypothesized to be a causative agent in the development of a similar type of kidney fibrosis with malignant transformation of the urothelium &#x02014; Balkan Endemic Nephropathy <xref rid="bb0030" ref-type="bibr">[6]</xref>. To date AAs have been shown to be among the 2% of the most potent known carcinogens <xref rid="bb0035" ref-type="bibr">[7]</xref>. IARC has classified herbal remedies containing species of the genus <italic>Aristolochia</italic> as carcinogenic to humans (Group 1) <xref rid="bb0040" ref-type="bibr">[8]</xref>, whereas naturally occurring mixtures of AAs are classified into Group 2A (probably carcinogenic to humans). AA is a direct-acting mutagen in TA100 and TA1537 <italic>Salmonella typhimurium</italic> strains, but is not mutagenic in the nitroreductase-deficient strains (TA98NR and TA100NR) <xref rid="bb0045" ref-type="bibr">[9]</xref>. AAs were found to be positive in the L5178Y mouse lymphoma assay and MN assay <xref rid="bb0050" ref-type="bibr">[10]</xref>. Renal tubular epithelial cells are very sensitive to AAs and undergo apoptosis or necrosis in response to this compound, with AAI being the more cytotoxic congener <xref rid="bb0055" ref-type="bibr">[11]</xref>. The carcinogenic effect of AAs is not fully elucidated but is associated with the formation of covalent AA-DNA adducts. Rats treated with AAs develop mutations in p53 gene and the presence of AA-DNA adducts in renal cortex and p53 mutations in tumor tissue were reported in patients with endemic nephropathy <xref rid="bb0060" ref-type="bibr">[12]</xref>.</p></sec><sec id="s0015"><label>3</label><title>Materials and methods</title><sec id="s0020"><label>3.1</label><title>Materials</title><p>A mixture of AAI and AAII was purchased from Sigma-Aldrich, UK. TRIzol reagent and GlutaMAX were obtained from (Invitrogen, UK) and RNeasy Total RNA Mini Kit and RNA later from (Qiagen, UK).</p></sec><sec id="s0025"><label>3.2</label><title>Cell culture</title><p>NRK-52E cells (ATCC, CRL-1571) were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal calf serum, penicillin 100&#x000a0;IU&#x000a0;ml<sup>&#x02212;&#x000a0;1</sup>, and streptomycin solution 100&#x000a0;&#x003bc;g&#x000a0;ml<sup>&#x02212;&#x000a0;1</sup> in a humidified 5% CO<sub>2</sub> incubator at 37&#x000a0;&#x000b0;C.</p></sec><sec id="s0030"><label>3.3</label><title>Cytotoxicity-determination of IC<sub>10</sub></title><p>A dose&#x02013;response curve for AAs was determined using the MTT assay <xref rid="bb0065" ref-type="bibr">[13]</xref>. Cells were exposed for 72&#x000a0;h in 96-well plates to a wide range of concentrations of AAs dissolved in DMSO and diluted to give a final concentration of 0.1% v/v DMSO. Control cells were exposed to DMSO alone (0.1% v/v). At least three separate experiments were conducted. The dose that caused approximately 10% cytotoxicity (IC<sub>10</sub>) at 72&#x000a0;h was selected for the transcriptomics studies.</p></sec><sec id="s0035"><label>3.4</label><title>Cell treatment</title><p>NRK-52E cells were cultured to confluence on 6-well plates. For transcriptomics studies, cells were exposed to AAs dissolved in DMSO (0.1% v/v) at the IC<sub>10</sub> concentration at 72&#x000a0;h (1.65&#x000a0;&#x003bc;M) or DMSO (0.1% v/v) alone. After 6&#x000a0;h, 24&#x000a0;h and 72&#x000a0;h the medium was removed and RNA was extracted from cells. For replication, three studies were conducted at each time point.</p></sec><sec id="s0040"><label>3.5</label><title>RNA isolation and microarray</title><p>From in vitro studies total RNA was isolated from DMSO (control) and AA-treated cells. TRIzol reagent was used for RNA isolation. Total RNA was purified using the RNeasy Total RNA Mini Kit (Qiagen) according to the manufacturer's instructions. RNA was checked for purity and integrity using Agilent 2001 Bioanalyzer (Agilent Technologies GmbH, Germany) before processing. Transcriptomics data was generated using GeneChip Rat Genome 230 2.0 The rat array provides comprehensive coverage of the transcribed rat genome and comprised of more than 31,000 probe sets, analyzing over 30,000 transcripts and variants from over 28,000 well-substantiated rat genes.</p></sec><sec id="s0045"><label>3.6</label><title>Microarray hybridization</title><sec id="s0050"><label>3.6.1</label><title>Target preparation</title><p>cDNA was prepared using the Affymetrix IVT express kit (Affymetrix, Santa Clara). cDNA synthesis and labeling were performed according to the manufacturer's procedures. Subsequent labeling of the samples was conducted by synthesis of Biotin-labeled complementary RNA (cRNA) using the GeneChip IVT labeling kit (Affymetrix). Purified cRNA was quantified using a spectrophotometer, and unfragmented samples were checked on the Bioanalyzer. Subsequently, cRNA samples were fragmented for target preparation according to the Affymetrix manual and checked on the Bioanalyzer. Samples were stored at &#x02212;&#x000a0;20&#x000a0;&#x000b0;C until ready to perform hybridization.</p></sec><sec id="s0055"><label>3.6.2</label><title>Hybridization</title><p>cRNA targets were hybridized on high-density oligonucleotide gene chips (Affymetrix Human Genome U133 Plus 2.0 and GeneChip Rat Genome 230 2.0 Arrays) according to the Affymetrix Eukaryotic Target Hybridization manual. The gene chips were washed and stained using the Affymetrix Fluidics Station 450 and Genechip Operating Software and scanned by means of an Affymetrix GeneArray scanner.</p></sec><sec id="s0060"><label>3.6.3</label><title>Microarray analysis</title><p>The intensity values of different genes (probe sets) generated by Affymetrix GeneChip Operating Software were imported into GeneSpring version 11 software (Agilent) for data analysis. The raw data files (CEL files) containing signal values for individual probes were pre-processed to generate one value per probeset. Pre-processing of arrays was done using GC-RMA (Robust Multiarray Analysis algorithm). To identify the differentially expressed (DE) probe sets, two sampled <italic>t</italic>-test (unpaired <italic>t</italic>-test) with a <italic>P</italic>-value &#x0003c;&#x000a0;0.05 and Benjamini&#x02013;Hochberg correction for multiple testing correction and a fold cut off of 2 was used. Comparisons were made between control DMSO-exposed and AA-exposed cells. Three studies were conducted at each time point.</p></sec><sec id="s0065"><label>3.6.4</label><title>Functional annotation</title><p>To understand the biological meaning behind the list of DE genes, Kyoto Encyclopaedia of Genes and Genomes database (KEGG) pathways analysis and Gene Ontology (GO) from DAVID website (The Database for Annotation, Visualization and Integrated Discovery) v 6.7 (<ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov" id="ir0020">http://david.abcc.ncifcrf.gov</ext-link>/) were used. Only GO and pathways with <italic>P</italic>-value &#x0003c;&#x000a0;0.05 (Benjamin&#x02013;Hochberg corrected) and with 5 or more genes were analyzed and discussed. In addition, Ingenuity Pathway Analysis (IPA) was used. Only pathways and functions with <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 (Fisher's exact test right-tailed) were analyzed and discussed.</p></sec><sec id="s0070"><label>3.6.5</label><title>Data deposition</title><p>MIAMI-compliant microarray data were deposited in the NCBI GEO database under accession number <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687%20" id="ir0025">GSE68687</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687" id="ir0030">http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68687</ext-link>.</p></sec></sec></sec><sec id="s0075"><label>4</label><title>Results</title><sec id="s0080"><label>4.1</label><title>Gene expression profile induced after aristolochic acids exposure</title><p>No genes were differentially expressed after 6&#x000a0;h and 24&#x000a0;h exposure to AAs, however at 72&#x000a0;h, 1204 genes were found to be differentially expressed. Both IPA and KEGG pathways identify p53 signaling as a top statistically significantly enriched pathway (<xref rid="t0005" ref-type="table">Table 1</xref>, <xref rid="t0010" ref-type="table">Table 2</xref>). Additionally after 72&#x000a0;h exposure genes involved in apoptosis, stress response, DNA damage and glutathione biosynthesis were identify (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>).</p></sec></sec><sec id="s0085"><label>5</label><title>Conclusion</title><p>Our results suggest that microarray analysis is a useful tool for detecting AA exposure <italic>in vitro</italic> and the gene expression analysis can identify the responses to toxicity and carcinogenicity of AAs in rat renal proximal tubule cells. In addition, the significantly altered genes were identify to be associated with cancer pathways and specifically p53 signaling, DNA damage responses and apoptosis.</p></sec></body><back><ref-list><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Mengs</surname><given-names>U.</given-names></name><name><surname>Lang</surname><given-names>W.</given-names></name><name><surname>Poch</surname><given-names>J.A.</given-names></name></person-group><source>Arch. Toxicol.</source><volume>51</volume><year>1982</year><fpage>107</fpage><lpage>119</lpage></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.H.</given-names></name><name><surname>Qiu</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.S.</given-names></name></person-group><source>Mutagenesis</source><volume>20</volume><year>2005</year><fpage>45</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">15644423</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Mengs</surname><given-names>U.</given-names></name></person-group><source>Arch. Toxicol.</source><volume>61</volume><year>1988</year><fpage>504</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">3190449</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Vanherweghem</surname><given-names>L.J.</given-names></name></person-group><source>J. Altern. Complement. Med.</source><volume>4</volume><year>1998</year><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">9553830</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Arlt</surname><given-names>V.M.</given-names></name><name><surname>Stiborova</surname><given-names>M.</given-names></name><name><surname>Schmeiser</surname><given-names>H.H.</given-names></name></person-group><source>Mutagenesis</source><volume>17</volume><year>2002</year><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">12110620</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Grollman</surname><given-names>A.P.</given-names></name><name><surname>Shibutani</surname><given-names>S.</given-names></name><name><surname>Moriya</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>F.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Moll</surname><given-names>U.</given-names></name><name><surname>Suzuki</surname><given-names>N.</given-names></name><name><surname>Fernandes</surname><given-names>A.</given-names></name><name><surname>Rosenquist</surname><given-names>T.</given-names></name><name><surname>Medverec</surname><given-names>Z.</given-names></name><name><surname>Jakovina</surname><given-names>K.</given-names></name><name><surname>Brdar</surname><given-names>B.</given-names></name><name><surname>Slade</surname><given-names>N.</given-names></name><name><surname>Turesky</surname><given-names>R.J.</given-names></name><name><surname>Goodenough</surname><given-names>A.K.</given-names></name><name><surname>Rieger</surname><given-names>R.</given-names></name><name><surname>Vukelic</surname><given-names>M.</given-names></name><name><surname>Jelakovic</surname><given-names>B.</given-names></name></person-group><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>104</volume><year>2007</year><fpage>12129</fpage><lpage>12134</lpage><pub-id pub-id-type="pmid">17620607</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><mixed-citation publication-type="other" id="or0005">G. LS, Z. E, Boca Raton, FL: CRC Press, 1997.</mixed-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="book" id="rf0035"><source>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans</source><volume>82</volume><year>2002</year><publisher-name>World Health Organization, International Agency for Research on Cancer</publisher-name><fpage>1</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">12687954</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Schmeiser</surname><given-names>H.H.</given-names></name><name><surname>Pool</surname><given-names>B.L.</given-names></name><name><surname>Wiessler</surname><given-names>M.</given-names></name></person-group><source>Cancer Lett.</source><volume>23</volume><year>1984</year><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">6378360</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Cifone</surname><given-names>M.A.</given-names></name><name><surname>Murli</surname><given-names>H.</given-names></name><name><surname>Erexson</surname><given-names>G.L.</given-names></name><name><surname>Mecchi</surname><given-names>M.S.</given-names></name><name><surname>Lawlor</surname><given-names>T.E.</given-names></name></person-group><source>Food Chem. Toxicol.</source><volume>42</volume><year>2004</year><fpage>2021</fpage><lpage>2028</lpage><pub-id pub-id-type="pmid">15500939</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Bakhiya</surname><given-names>N.</given-names></name><name><surname>Arlt</surname><given-names>V.M.</given-names></name><name><surname>Bahn</surname><given-names>A.</given-names></name><name><surname>Burckhardt</surname><given-names>G.</given-names></name><name><surname>Phillips</surname><given-names>D.H.</given-names></name><name><surname>Glatt</surname><given-names>H.</given-names></name></person-group><source>Toxicology</source><volume>264</volume><year>2009</year><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">19643159</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Slade</surname><given-names>N.</given-names></name><name><surname>Moll</surname><given-names>U.M.</given-names></name><name><surname>Brdar</surname><given-names>B.</given-names></name><name><surname>Zoric</surname><given-names>A.</given-names></name><name><surname>Jelakovic</surname><given-names>B.</given-names></name></person-group><source>Mutat. Res.</source><volume>663</volume><year>2009</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19428366</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T.</given-names></name></person-group><source>J. Immunol. Methods</source><volume>65</volume><year>1983</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">6606682</pub-id></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgements</title><p>This study was funded primarily by the <funding-source id="gts0005">6th EU Framework project</funding-source> (LSHB-CT-2006-037712) carcinoGENOMICS.</p></ack></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>Chemical structure of aristolochic acid I and II.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>KEGG pathways enriched after 72&#x000a0;h exposure to AAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">KEGG pathway</th><th align="left">No. of genes involved in pathway</th><th align="left">Total no. of genes involved in the pathway (%)</th><th align="left"><italic>P</italic>-value (Benjamini)</th></tr></thead><tbody><tr><td align="left">p53 signaling pathway</td><td align="left">16</td><td align="char">1.9</td><td align="char">8.5E&#x000a0;&#x02212;&#x000a0;8 (1.3E&#x000a0;&#x02212;&#x000a0;5)</td></tr><tr><td align="left">Pathways in cancer</td><td align="left">30</td><td align="char">3.6</td><td align="char">8.6E&#x000a0;&#x02212;&#x000a0;5 (6.4E&#x000a0;&#x02212;&#x000a0;3)</td></tr></tbody></table></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Ingenuity pathways enriched after 72&#x000a0;h exposure to AAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Ingenuity canonical pathway</th><th align="left">No. of genes involved in the pathway</th><th align="left"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">p53 signaling</td><td align="char">17/98</td><td align="char">9.65E&#x000a0;&#x02212;&#x000a0;08</td></tr><tr><td align="left">Glutathione biosynthesis</td><td align="char">3/3</td><td align="char">4.96E&#x000a0;&#x02212;&#x000a0;05</td></tr><tr><td align="left">ATM signaling</td><td align="char">10/59</td><td align="char">5.20E&#x000a0;&#x02212;&#x000a0;05</td></tr><tr><td align="left">Cell cycle: G2/M DNA damage checkpoint regulation</td><td align="char">9/49</td><td align="char">6.44E&#x000a0;&#x02212;&#x000a0;05</td></tr><tr><td align="left">Molecular mechanisms of cancer</td><td align="char">8/99</td><td align="char">6.74E&#x000a0;&#x02212;&#x000a0;05</td></tr></tbody></table></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>GO enriched after 72&#x000a0;h exposure to AAs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GO</th><th align="left">No. of genes involved in pathway</th><th align="left">Total no. of genes involved in the pathway (%)</th><th align="left"><italic>P</italic>-value (Benjamini)</th></tr></thead><tbody><tr><td align="left">Regulation of apoptosis</td><td align="char">61</td><td align="char">7.4</td><td align="char">1.80E&#x000a0;&#x02212;&#x000a0;08 (5.10E&#x000a0;&#x02212;&#x000a0;05)</td></tr><tr><td align="left">Release of cytochrome c from mitochondria</td><td align="char">8</td><td align="char">1</td><td align="char">1.40E&#x000a0;&#x02212;&#x000a0;05 (3.70E&#x000a0;&#x02212;&#x000a0;03)</td></tr><tr><td align="left">Regulation of cell proliferation</td><td align="char">51</td><td align="char">6.2</td><td align="char">3.30E&#x000a0;&#x02212;&#x000a0;05 (7.60E&#x000a0;&#x02212;&#x000a0;03)</td></tr><tr><td align="left">Apoptotic mitochondrial changes</td><td align="char">8</td><td align="char">1</td><td align="char">1.50E&#x000a0;&#x02212;&#x000a0;04 (2.40E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Blood vessel morphogenesis</td><td align="char">20</td><td align="char">2.4</td><td align="char">2.70E&#x000a0;&#x02212;&#x000a0;04 (4.20E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Tissue remodeling</td><td align="char">11</td><td align="char">1.3</td><td align="char">2.80E&#x000a0;&#x02212;&#x000a0;04 (4.10E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Response to abiotic stimulus</td><td align="char">33</td><td align="char">4</td><td align="char">2.90E&#x000a0;&#x02212;&#x000a0;04 (4.00E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Cellular response to stress</td><td align="char">35</td><td align="char">4.2</td><td align="char">3.20E&#x000a0;&#x02212;&#x000a0;04 (4.00E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">DNA damage response, signal transduction resulting in induction of apoptosis</td><td align="char">7</td><td align="char">0.8</td><td align="char">3.60E&#x000a0;&#x02212;&#x000a0;04 (4.30E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Regulation of cell adhesion</td><td align="char">15</td><td align="char">1.8</td><td align="char">4.50E&#x000a0;&#x02212;&#x000a0;04 (4.60E&#x000a0;&#x02212;&#x000a0;02)</td></tr><tr><td align="left">Response to DNA damage stimulus</td><td align="char">24</td><td align="char">2.9</td><td align="char">4.80E&#x000a0;&#x02212;&#x000a0;04 (4.70E&#x000a0;&#x02212;&#x000a0;02)</td></tr></tbody></table></table-wrap></floats-group></article>